Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Breast ; 72: 103577, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37722319

RESUMEN

OBJECTIVES: We aimed to evaluate the pCR rate in patients receiving NAC for the treatment of breast cancer (BC) in a multicenter cohort in Brazil. Additionally, we aimed to use RWD to assess the impact of pCR on OS and DFS. METHODS: This was a retrospective, multicenter cohort study that included female patients over 18 years of age who were diagnosed with nonmetastatic breast cancer and received NAC. OS and DFS at five years were estimated by the Kaplan‒Meier method. Additionally, we conducted a multivariate analysis to identify factors that were significantly associated with pCR and OS. RESULTS: From 2011 to 2020, 1891 patients were included in the study, and 421 (22,3%) achieved pCR (ypT0 ypN0). Considering the presence of residual DCIS, pCR was achieved in 467 patients (23,5%). The pCR rate varied between the subtypes: HER-2+ (p = 0,016) and clinical stage IIIA and IIIB (p < 0,001). Among HER-2+ patients, those who received trastuzumab had a significantly higher pCR rate than those who did not receive trastuzumab (p < 0.0001). Similarly, patients with TNBC who received treatment with platinum-based regimens also showed higher pCR rates (p < 0.0001). OS was grouped according to pCR status, and the OS rate was 88,3% in the pCR group and 58.1% in the non-pCR group (p < 0.0001). The five-year DFS was 92.2% in the pCR group and 64.3% in the non-pCR group (p < 0.0001). CONCLUSION: The pCR rate and its prognostic value varied across BC subtypes. In our study, pCR could be used as a surrogate of favorable clinical outcome, as it was associated with higher OS and DFS rates.


Asunto(s)
Neoplasias de la Mama , Humanos , Femenino , Adolescente , Adulto , Neoplasias de la Mama/patología , Brasil , Terapia Neoadyuvante , Estudios Retrospectivos , Estudios de Cohortes , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Pronóstico , Trastuzumab/uso terapéutico , Supervivencia sin Enfermedad
2.
Salud(i)ciencia (Impresa) ; 16(4): 411-414, sept. 2008. tab
Artículo en Portugués | LILACS | ID: biblio-836565

RESUMEN

Objetivo: Avaliar (evaluar) os resultados obtidos (logrados)em um grupo de pacientes com diagnóstico de endometriose infiltrativa profunda (EIP) submetidas (sometidas)a tratamento cirúrgico (quirúrgico) no Hospital do Servidor Público Estadual «Francisco Morato de Oliveira¼, São Paulo, Brasil. Casuística e métodos: Estudo retrospectivo com análise dos casos através de levantamento de seus (investigación de sus) registros em prontuários (historias clínicas). Foram incluídas 23 pacientes operadas entre outubro de 1999 e setembro de 2006...


Purpose: to evaluate the results of a group of patients with deep infiltrating endometriosis that were treated with surgery at the Gynecological Endoscopy Service ofthe Hospital do Servidor Público Estadual «Francisco Morato de Oliveira¼, São Paulo, Brazil. Methods: a retrospective analysis was accomplished with data from the records. We present 23 patients treated between October 1999 and September 2006...


Asunto(s)
Endometriosis/cirugía , Laparoscopía , Abdomen Agudo , Dismenorrea , Dispareunia , Infertilidad , Mioma , Dolor
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA